Sugi Predict

Sugi Predict / Compounds / SCHEMBL690395

SCHEMBL690395

SCHEMBL690395

O=C(Nc1ccc2c(c1)CCN(Cc1nc[nH]n1)C2)c1ccccc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MTTP P55157 12/20 0.51
▸ APOB P04114 10/20 0.51
▸ SMO Q99835 1/20 0.51
▸ GAA P10253 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ KDR P35968 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6967435 0.88 APOB (0.41) MTTPAPOBSMOGAAMAPT
SCHEMBL8620976 0.87 SMO (0.52) MTTPAPOBSMOGAAKDM4E
SCHEMBL6805186 0.86 MTTP (0.49) MTTPAPOBSMOGAAKDM4E
SCHEMBL8200984 0.86 APOB (0.62) MTTPAPOBSMOGAAKDM4E
SCHEMBL690014 0.85 SMO (0.52) MTTPAPOBSMOGAAKDM4E
SCHEMBL7041135 0.85 SMO (0.52) MTTPAPOBSMOGAAKDM4E
SCHEMBL8470782 0.85 PRMT5 (0.40) —
SCHEMBL6502283 0.85 NOD1 (0.40) MTTPAPOBKDR
SCHEMBL8213404 0.84 MTTP (0.58) MTTPAPOBSMOGAAKDM4E
SCHEMBL8507709 0.84 MTTP (0.58) MTTPAPOBSMOGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1806149-A1 SOLID MEDICINAL PREPARATION IMPROVED IN SOLUBILITY AND STABILITY AND PROCESS FOR PRODUCING THE SAME Japan Tobacco, Inc. (JP) 2007-07-11 — — EP claimed
US-20060153913-A1 Solid formulation with improved solubility and stability, and method for producing said formulation JAPAN TOBACCO INC. (JP) 2006-07-13 — — US claimed
US-9314438-B2 Elevation of the plasma HDL-cholesterol level AARHUS UNIVERSITET (DK) 2016-04-19 — — US disclosed
EP-1951690-B1 HETEROCYCLIC CETP INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-03-28 — — EP disclosed
EP-1954668-B9 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-03-21 — — EP disclosed
EP-2094643-B1 N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES BRISTOL MYERS SQUIBB CO (US) 2012-02-29 — — EP disclosed
EP-1954668-B1 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-09-28 — — EP disclosed
US-7919506-B2 Dibenzyl amine compounds and derivatives PFIZER INC. (US) 2011-04-05 — — US disclosed
US-20110038827-A1 ELEVATION OF THE PLASMA HDL-CHOLESTEROL LEVEL JEPPESEN, PER BENDIX (DK) 2011-02-17 — — US disclosed
US-7888376-B2 Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-15 — — US disclosed
US-7468378-B2 Substituted quinoline compounds PFIZER INC. (US) 2008-12-23 — — US disclosed
EP-1806149-A1 SOLID MEDICINAL PREPARATION IMPROVED IN SOLUBILITY AND STABILITY AND PROCESS FOR PRODUCING THE SAME Japan Tobacco, Inc. (JP) 2007-07-11 — — EP disclosed
US-20060247272-A1 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds PFIZER INC 2006-11-02 — — US disclosed
US-20060166999-A1 Use of microsomal triglyceride transfer protein (MTP) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (PPTRL) BAYER AKTIENGESELLSCHAFT (DE) 2006-07-27 — — US disclosed
US-20060153913-A1 Solid formulation with improved solubility and stability, and method for producing said formulation JAPAN TOBACCO INC. (JP) 2006-07-13 — — US disclosed
US-20050234099-A1 Substituted quinoline compounds PFIZER INC 2005-10-20 — — US disclosed
US-6140343-A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS WHICH ARE USED TO ELEVATE HIGHDENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER LOW DENSITY LIPOPROTEIN-CHOLESTEROL AND TRIGLYCERIDES; FOR TREATING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, OBESITY PFIZER (US) 2000-10-31 — — US disclosed
JP-2000169395-A MEDICINE FOR LOWERING BLOOD LEVEL OF LIPOPROTEIN (A) PFIZER PROD INC 2000-06-20 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247272-A1 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds APOB, LDLR, CETP MTTP 4/4885APOB 1/4885SMO 2581/4885
US-20050234099-A1 Substituted quinoline compounds APOB, APOL1, MTPN MTTP 9/4885APOB 1/4885SMO 4789/4885
US-20110038827-A1 ELEVATION OF THE PLASMA HDL-CHOLESTEROL LEVEL CETP, CYP46A1, NPC1L1 MTTP 5/4885APOB 12/4885SMO 3747/4885
US-20060153913-A1 Solid formulation with improved solubility and stability, and method for producing said formulation ABCG2, SORD, SRI MTTP 1276/4885APOB 2105/4885SMO 260/4885
US-20060166999-A1 Use of microsomal triglyceride transfer protein (MTP) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (PPTRL) MTTP, APOB, CETP MTTP 1/4885APOB 2/4885SMO 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.